Trials / Completed
CompletedNCT01364415
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
A Phase I, Multi-center, Open-label, Dose Escalation Study of Pasireotide (SOM230) LAR in Patients With Advanced Neuroendocrine Tumors (NETs)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study designed to determine the Maximum Tolerated Dose (MTD) for patients with advanced Neuroendocrine Tumors (NETs) and to characterize the safety, tolerability, Pharmacokinetics and preliminary efficacy of pasireotide LAR administered i.m. once every 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pasireotide LAR |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2011-06-02
- Last updated
- 2020-12-21
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01364415. Inclusion in this directory is not an endorsement.